SRI and breast carcinoma: To date, the overexpression of sorcin has been observed in a number of multidrug-resistant (MDR) cell lines and several tumor cell types, including human colorectal cancer cells, human gastric cancer cells (9,10), leukemia (11,12), ovarian and breast cancer cells (13,14) and lung cancer (15).